Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pds Biotechnology Corp (PDSB)

Pds Biotechnology Corp (PDSB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,114
  • Shares Outstanding, K 36,679
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,940 K
  • 60-Month Beta 1.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.44
Trade PDSB with:

Options Overview Details

View History
  • Implied Volatility 199.51% ( +17.10%)
  • Historical Volatility 97.16%
  • IV Percentile 95%
  • IV Rank 49.69%
  • IV High 340.17% on 05/02/24
  • IV Low 60.58% on 05/15/23
  • Put/Call Vol Ratio 0.02
  • Today's Volume 1,046
  • Volume Avg (30-Day) 507
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 11,759
  • Open Int (30-Day) 12,331

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.37
  • Number of Estimates 2
  • High Estimate -0.33
  • Low Estimate -0.40
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -15.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.59 +44.02%
on 04/19/24
4.00 -6.70%
on 05/06/24
+0.50 (+15.48%)
since 04/05/24
3-Month
2.59 +44.02%
on 04/19/24
6.68 -44.16%
on 03/04/24
-1.64 (-30.54%)
since 02/06/24
52-Week
2.59 +44.02%
on 04/19/24
10.27 -63.68%
on 06/01/23
-2.80 (-42.88%)
since 05/05/23

Most Recent Stories

More News
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates

USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around...

ONCY : 1.1800 (+0.85%)
ONC.TO : 1.61 (+0.62%)
TCRX : 8.81 (+2.92%)
BMY : 43.90 (-0.20%)
PDSB : 3.73 (-2.36%)
CCCC : 6.71 (-0.45%)
S&P Futures Tick Higher Ahead of Key U.S. Inflation Data, U.S. Debt-Ceiling Talks in Focus

June S&P 500 futures (ESM23) are trending up +0.17% this morning after the S&P 500 and Nasdaq 100 closed sharply higher on Thursday as blowout guidance from Nvidia and progress on debt ceiling talks boosted...

ESM23 : 4,453.35s (+0.61%)
NVDA : 921.40 (+3.77%)
RL : 166.66 (+0.01%)
BBY : 74.40 (-0.09%)
INTC : 30.97 (+0.23%)
RIO.LN : 5,467.001 (+0.46%)
GPS : 22.21 (+2.87%)
MRVL : 69.82 (+1.91%)
WDAY : 249.91 (-2.29%)
TLRY : 2.05 (-2.38%)
PDSB : 3.73 (-2.36%)
MDB : 365.67 (+0.78%)
3 Deeply Undervalued Stocks That Could Double Your Money

These cutting-edge biotech stocks hold tremendous upside potential.

PDSB : 3.73 (-2.36%)
NTLA : 23.72 (+0.51%)
VERV : 6.41 (unch)
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study

A mid-stage study data shows that treatment with PDS Biotech's (PDSB) lead candidate in advanced HPV-positive cancer patients achieved a median overall survival of 21 months.

CANF : 2.11 (+0.96%)
AMLX : 1.99 (-1.97%)
ACER : 0.6601 (-17.95%)
PDSB : 3.73 (-2.36%)
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027

Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing...

BIOV.CN : 0.0700 (-12.50%)
BVAXF : 0.0548 (-7.12%)
SGEN : 228.74 (-0.07%)
ZLAB : 16.91 (+4.06%)
PDSB : 3.73 (-2.36%)
ILMN : 118.98 (+0.89%)
GILD : 65.54 (+1.17%)
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027

/PRNewswire/ -- The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing CAGR. Cervical...

ZLAB : 16.91 (+4.06%)
BIOV.CN : 0.0700 (-12.50%)
BVAXF : 0.0548 (-7.12%)
SGEN : 228.74 (-0.07%)
PDSB : 3.73 (-2.36%)
ILMN : 118.98 (+0.89%)
GILD : 65.54 (+1.17%)
PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update

Announced results from two of the ongoing Phase 2 clinical trials of PDS0101 in multiple, difficult-to-treat HPV16-related cancers presented at the...

PDSB : 3.73 (-2.36%)
PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications

Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse events...

PDSB : 3.73 (-2.36%)
PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology Meeting

PDS0202 neutralized multiple strains of influenza and provided protection against infection in preclinical studies...

PDSB : 3.73 (-2.36%)
PDS Biotechnology Appoints Spencer Brown as Senior Vice President, General Counsel

Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)...

PDSB : 3.73 (-2.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary...

See More

Key Turning Points

3rd Resistance Point 4.20
2nd Resistance Point 4.10
1st Resistance Point 3.92
Last Price 3.73
1st Support Level 3.63
2nd Support Level 3.52
3rd Support Level 3.34

See More

52-Week High 10.27
Fibonacci 61.8% 7.34
Fibonacci 50% 6.43
Fibonacci 38.2% 5.52
Last Price 3.73
52-Week Low 2.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar